Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hawaii Biotech appoints Avantogen CEO to its board of directors

This article was originally published in Scrip

Executive Summary

Hawaii Biotech, a biotechnology company focused on vaccine development, has appointed Dr William Ardrey to its board of directors. Dr Ardrey is CEO of Avantogen, which develops drugs in the oncology and vaccine markets, and which has a substantial stake in Hawaii Biotech. Dr Ardrey will both support Hawaii Biotech's development activities – the company recently began a trial into a vaccine for West Nile virus, and plans a Phase I trial for dengue fever next year – and bring investment to the company, with Avantogen planning to purchase additional shares in the company. The position is effective from October 21st.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts